Heart rate management: a therapeutic goal throughout the cardiovascular continuum
Author:
- J. L. ZamoranoJZJ. L. Zamorano
- 1 August 2008
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 10 (Suppl F) , F17-F21
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina PectorisDrugs, 2007
- The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient OutcomesCirculation, 2006
- Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) StudyAmerican Heart Journal, 2006
- Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosisJournal Of Hypertension, 2006
- La fréquence cardiaque, facteur pronostique majeur du risque cardiovasculaireTherapies, 2006
- Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable anginaEuropean Heart Journal, 2005
- Heart-Rate Profile during Exercise as a Predictor of Sudden DeathNew England Journal of Medicine, 2005
- Heart Rate Lowering by Specific and Selective If Current Inhibition with IvabradineDrugs, 2004
- Heart rate and cardiovascular mortality: The Framingham studyAmerican Heart Journal, 1987
- Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trialsThe American Journal of Cardiology, 1986